摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯 | 155445-28-6

中文名称
2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯
中文别名
——
英文名称
methyl 2-methyl-4H-furo[3,2-b]pyrrole-5-carboxylate
英文别名
——
2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯化学式
CAS
155445-28-6
化学式
C9H9NO3
mdl
MFCD05248539
分子量
179.175
InChiKey
NJMHLPYIHMAHRE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    297.2±35.0 °C(Predicted)
  • 密度:
    1.290±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.222
  • 拓扑面积:
    55.2
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:286e42ffa4cc29645f4d400a806baf0f
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    通过四组分 Ugi 反应的改进合成含有 5-氨基甲酰基吡嗪-3-one 片段的退火氮杂杂环
    摘要:
    描述了通过四组分 Ugi 缩合的新型修饰,方便合成新型咪唑和吡咯稠合的 1-oxo-1,2,3,4-四氢吡嗪杂环结构。证明了所开发的各种取代化合物合成方法的实用性和多功能性,并讨论了所涉及化学的范围和局限性。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)
    DOI:
    10.1002/ejoc.200500522
  • 作为产物:
    描述:
    methyl 2-[(dimethylamino)methyl]-4H-furo[3,2-b]pyrrole-5-carboxylate碘甲烷 、 sodium tetrahydroborate 、 盐酸 作用下, 以 甲醇 为溶剂, 反应 1.0h, 以53%的产率得到2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯
    参考文献:
    名称:
    FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE
    摘要:
    这项发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括该发明中化合物的药物组合物。该发明还提供了用于治疗和预防神经系统疾病,如神经精神病和神经退行性疾病,以及疼痛、共济失调和抽搐的方法。该发明中的化合物具有一般结构:其中A为NH或S。Q是从CR1和N中选择的成员。X和Y分别是从O、S、CR2、N和NH中独立选择的成员。R1、R2和R4是从H和F中独立选择的成员,前提是至少选择R1、R2和R4中的一个成员为F。R6是从O−X+和OH中选择的成员,其中X+是正离子,从无机正离子和有机正离子中选择的成员。
    公开号:
    US20080004327A1
点击查看最新优质反应信息

文献信息

  • Derivatives of Furo[3,2-b]pyrrole
    作者:Alžbeta Krutošíková、Miloslava Dandárová、Vladimír Bobošík
    DOI:10.1135/cccc19940473
    日期:——

    A number of methyl 2-substituted, 2,3-disubstituted-4H-furo[3,2-b]pyrrole-5-carboxylates (V - VII) and methyl 1H-benzo[b]furo[3,2-b]pyrrole-2-carboxylate (VIII) was prepared by the thermolysis of corresponding methyl 2-azido-3-(R1,R2-substituted-2-furyl)propenoates (I - IV). N-Methyl and N-benzyl derivatives IX - XVI were prepared at the phase-transfer catalysis conditions. Hydrolysis of some N-methyl and N-benzyl substituted esters furnished corresponding acids XVII - XXII. The hydrazides XXIII - XXX were obtained from corresponding esters and hydrazine hydrate. The preparation of 1-benzylbenzo[b]furo[3,2-b]pyrrole (XXXI) is described as well.

    通过相应的甲基2-取代的、2,3-二取代-4H-呋喃[3,2-b]吡咯-5-羧酸酯(V - VII)和甲基1H-苯并[b]呋喃[3,2-b]吡咯-2-羧酸酯(VIII)的热解制备了一些产物。在相转移催化条件下制备了N-甲基和N-苄基衍生物IX - XVI。对一些N-甲基和N-苄基取代酯的水解得到了相应的酸XVII - XXII。通过相应的酯和联氨醇水合物得到了肼XXXIII - XXX。文中也描述了1-苄基苯并[b]呋喃[3,2-b]吡咯(XXXI)的制备方法。
  • Synthesis and antibacterial activity of furo[3,2-b]pyrrole derivatives
    作者:Ivana Zemanová、Renata Gašparová、Andrej Boháč、Tibor Maliar、Filip Kraic、Gabriela Addová
    DOI:10.24820/ark.5550190.p010.240
    日期:——
    synthesized by reaction of appropriate triazinone with POCl3 and subsequent treating of 8-chloro derivative with sodium ethoxide in ethanol. Furo[3,2-b]pyrrole-5carboxylates were hydrolysed to form acids, which underwent one-pot decarboxylation with TFA and formylation of the in situ formed furo[3,2-b]pyrrole with triethyl orthoformate to give 5-carbaldehydes. Hydrazinolysis of bis-esters led to bis-carbohydrazides
    8-乙氧基呋喃[2',3':4,5]吡咯并[1,2-d][1,2,4]三嗪通过适当的三嗪酮与POCl3反应,然后用乙醇钠处理8-氯衍生物合成在乙醇中。Furo[3,2-b]pyrrole-5carboxylates 水解形成酸,用 TFA 进行一锅脱羧,原位形成的 furo[3,2-b]pyrrole 与原甲酸三乙酯甲酰化得到 5-甲醛。双酯的肼解导致双碳酰肼,其随后在微波辐射下在乙酸中环化以形成具有不寻常手性的吡嗪或乙酰胺衍生物。评价制备的化合物对大肠杆菌和藤黄微球菌的抗菌活性。
  • Synthesis and Reactions of 8-Hydrazinofuro[2',3':4,5]pyrrolo-[1,2-d][1,2,4]triazines
    作者:Alžbeta Krutošíková、Slavomír Mastik、Miloslava Dandárová、Antonín Lyčka
    DOI:10.1135/cccc19971612
    日期:——

    5-Ethyl-8-hydrazinofuro[2',3':4,5]pyrrolo[1,2-d][1,2,4]triazine (4a) and its 2-methyl derivative 4b were prepared from 4H-furo[3,2-b]pyrrole-5-carbohydrazides 1a and 1b, respectively. Compounds 1a and 1b reacted with triethyl orthopropionate to give 2a and 2b which afforded with phosphorus(V) sulfide corresponding thiones 3a and 3b. The title compounds 4a and 4b were made by treatment of 3a and 3b with hydrazine hydrate. By reactions of triethyl orthoesters with the title compounds and similar derivatives furo[2'3':4,5]pyrrolo[1,2-d][1,2,4]triazolo[3,4-f][1,2,4]triazines 5a-5j were prepared. Reactions of compounds 4 with some aldehydes and isocyanates led to hydrazones 6a-6c and semicarbazones 7a and 7b, respectively.

    从4H-呋喃[3,2-b]吡咯-5-羟基脲化合物1a和1b分别合成了5-乙基-8-叠氮基呋喃[2',3':4,5]吡咯[1,2-d][1,2,4]三嗪(4a)及其2-甲基衍生物4b。化合物1a和1b与正丙酸三乙酯反应得到2a和2b,再与五价磷磺化合物反应形成相应的硫醚3a和3b。通过硫醚3a和3b与叠氮酸水合物反应制备了标题化合物4a和4b。通过正丙酸酯与标题化合物及类似衍生物的反应制备了呋喃[2'3':4,5]吡咯[1,2-d][1,2,4]三唑[3,4-f][1,2,4]三嗪5a-5j。化合物4与一些醛和异氰酸酯反应得到叠氮酮6a-6c和半胍酮7a和7b。
  • Fused heterocyclic inhibitors of D-amino acid oxidase
    申请人:Heffernan L. R. Michele
    公开号:US20080058395A1
    公开(公告)日:2008-03-06
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. Also provided are methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein Q is a member selected from O, S, CR 1 and N, X and Y are members independently selected from CR 2 , O, S, N and NR 3 .
    本发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括该发明化合物的制药组合物。同时,还提供了治疗和预防神经系统疾病,如神经精神疾病和神经退行性疾病,以及疼痛、共济失调和惊厥的方法。该发明化合物具有以下一般结构:其中Q是从O、S、CR1和N中选择的成员,X和Y是独立选择自CR2、O、S、N和NR3的成员。
  • Fluoro-substituted inhibitors of D-amino acid oxidase
    申请人:Sepracor Inc.
    公开号:US07884124B2
    公开(公告)日:2011-02-08
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O−X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.
    本发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括本发明化合物的制药组合物。本发明还提供了用于治疗和预防神经系统疾病,如神经精神疾病和神经退行性疾病,以及疼痛、共济失调和抽搐的方法。本发明化合物具有以下一般结构: 其中A为NH或S。Q为选择自CR1和N的成员。X和Y是独立选择自O、S、CR2、N和NH的成员。R1、R2和R4是独立选择自H和F的成员,但至少选择自R1、R2和R4中的一个成员为F。R6为选择自O−X+和OH的成员,其中X+为正离子,其为选择自无机正离子和有机正离子的成员。
查看更多

同类化合物

顺式-六氢呋喃并[3,4-C]吡咯 甲基4-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸酯 氮杂环丁烷并[1,2-a]呋喃并[2,3-c]吡咯 夫沙瑞汀A 呋喃并吡咯甲酸 六氢-1H-呋喃并[3,4-c]吡咯 六氢-1H-呋喃并[3,4-C]吡咯 八氢-呋喃并[3,2-c]吡啶 乙基4,6-二氢-5H-呋喃并[2,3-c]吡咯-5-羧酸酯 6H-呋喃并[2,3-b]吡咯-5-羧酸甲酯 6-甲基-6H-呋喃并[2,3-b]吡咯-5-羧酸 6-甲基-6H-呋喃并[2,3-b]吡咯-5-甲酰肼 4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 4H-呋喃并[3,2-b]吡咯-5-羧酸,2-甲酰基-,甲基酯 4H-呋喃并[3,2-b]吡咯 4H-呋喃并[3,2-B!吡咯-5-羧酸甲酯 4-甲基呋喃[3,2-b]吡咯-5-羧酸乙酯 4-甲基-4H-呋喃并[3,2-b]吡咯 4-甲基-4H-呋喃并[3,2-B]吡咯-5-甲酸 365-苄基六氢-1H-呋喃[34-c]吡咯 3-溴-4H-呋喃并[3,2-b]吡咯-5-羧酸 3-溴-4H-呋喃并[3,2-b]吡咯-5-甲酸乙酯 2-苯基-4H-呋喃并[3,2-b]吡咯-5-羧酸 2-甲酰基-6-甲基-6H-呋喃并[2,3-b]吡咯-5-羧酸 2-甲酰基-4-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸 2-溴-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-溴-4H-呋喃并[3,2-B]吡咯-5-羧酸 2-(4-甲氧基苯基)-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-(4-甲氧基苯基)-4H-呋喃并[3,2-b]吡咯-5-羧酸 2,3,3A,4-四氢-5H-呋喃并[3,2-b]吡咯-5-酮 1-(4H-呋喃并[3,2-b]吡咯-4-基)乙酮 1-(2-甲基-4H-呋喃并[3,2-b]吡咯-4-基)乙酮 (9ci)-1-甲基-1H-呋喃并[3,4-b]吡咯-4,6-二酮 (4-甲基-4H-呋喃并[3,2-b]吡咯-5-基)甲醇 (3aR,6aR)-4-乙酰基六氢-2H-呋喃并[3,2-b]吡咯-2-酮 5-(3-chloropropyl)hexahydro-1H-furo[3,4-c]pyrrole Methyl 2-[2-cyano-2-(methoxycarbonyl)vinyl]-6-methoxyfuro[2,3-b]pyrrole-5-carboxylate Methyl 6-methoxymethyl-2-(3,3,6,6-tetramethyl-1(2H),8(7H)-dioxo-3,4,5,6-tetrahydro-9H-xanthen-9-yl)furo[2,3-b]pyrrole-5-carboxylate methyl 2-cyano-6-(methoxymethyl)furo[2,3-b]pyrrole-5-carboxylate Methyl 2-(2,2-dicyanovinyl)-6-methoxymethylfuro[2,3-b]pyrrole-5-carboxylate (1R,5S,1'S)-1,5-dimethyl-8-phenylethyl-2-oxa-8-azabicyclo[3.3.0]octane-3,7-dione (1S,5R,1'S)-1,5-dimethyl-8-phenylethyl-2-oxa-8-azabicyclo[3.3.0]octane-3,7-dione {3-[2-(4-chloro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-propyl}-phosphonic acid diethyl ester methyl 4-(3,4-dichlorobenzyl)-2-formylfuro[3,2-b]pyrrole-carboxylate (3aR,6aS)-5-benzyl-3a,6a-dimethyltetrahydro-1H-furo[3,4-c]pyrrole-1,3(3aH)-dione (1R,2R,6R,8R,15S)-10,14-aza-4,4-dimethyl-11-oxo-1-mesyloxy-3,5,7-trioxa-tetracyclo[7.6.0.02,6.010,15]pentadecane 5-methyl-1,3-bis(3-oxobutyl)dihydro-1H-furo[3,4-c]pyrrole-4,6(5H,6aH)-dione